叮当健康旗下叮当快药凭借多年药学服务实践，与国药控股、首都医科大学附属北京安贞医院、宣武医 院、复旦大学药学院、北京大学药学院等机构共同成为该标准核心起草单位。 近日，T/CAPC 021—2026《零售药店专科药师药学服务能力评价指南》团体标准正式发布，这是我国 零售药店领域首部针对专科药师药学服务能力的系统性评价文件，填补了行业标准空白。 据了解，该标准明确了专科药师资质、职责、知识、技能及素养五大维度，构建了处方调剂、用药咨 询、用药评估、随访、药历、宣教、药物警戒等全流程药学服务能力评价体系。叮当快药依托多年来 7*24小时在线药学服务、处方审核、用药随访等药师服务的实践经验，为药师用药评估、风险防范等药 师核心能力要求提供了参考依据。 业内人士认为，该标准发布标志着零售药店向"专业化健康服务终端"转型迈出关键一步，通过能力进阶 路径与评价工具，推动药店人才梯队建设与服务分级，提升慢病管理、特殊人群用药等专业能力，助力 分级诊疗改革。 作为起草单位之一，叮当快药始终以药师专业能力为核心战略，依托线上线下一体化模式，构建起专业 药师团队，7×24小时为提供用户提供在线用药咨询、处方审核、慢病随访等全周期 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：600538 证券简称：国发股份 公告编号：临2026-005 北海国发川山生物股份有限公司 关于上海证券交易所对公司业绩预告相关事项问询函的回复公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 公司预计2025年度实现营业收入约3.3亿元，扣除与主营业务无关的业务收入和不具备商业实质的营业 收入仍为3.3亿元；归属于母公司所有者的净利润-0.85亿元。请公司补充披露：（1）根据《上海证券交 易所上市公司自律监管指南第2号一一业务办理》附件第七号《财务类退市指标：营业收入扣除》有关 规定，说明营业收入扣除相关情况，包括但不限于扣除项目、金额、相关业务开展情况及扣除原因等， 并逐项核实并说明是否存在其他应当扣除尚无扣除的情况；（2）按主要产品类别或业务板块，列示 2025年度预计实现营业收入的具体金额、占比、毛利率及同比变动情况，并说明主要影响因素；（3） 各业务板块前五大客户情况，包括客户名称、合同签订时间、合作期限、是否新增客户或关联方、销售 内容、销售金额、应 ...

医药流通业务增长与区域市场及行业趋势匹配 北海国发川山生物股份有限公司（以下简称"公司"）近日就上海证券交易所《关于北海国发川山生物股 份有限公司业绩预告相关事项的问询函》发布专项说明公告。公告显示，公司2025年度预计实现营业收 入约3.3亿元，归属于母公司所有者的净利润-0.85亿元，并拟计提商誉减值准备约6244.77万元。天健会 计师事务所对相关财务事项进行了审慎核查，认为公司营业收入扣除合规，医药流通业务增长合理，商 誉减值计提充分。 营业收入扣除合规 医药流通业务成主要增长引擎 根据公告，公司2025年度营业收入32,956.29万元，扣除与主营业务无关的业务收入和不具备商业实质的 营业收入248.08万元后，剩余32,708.21万元。扣除项目主要包括房屋出租、销售废品收入223.54万元及 医药流通贸易业务收入24.54万元（已按净额法调整），占营业收入比重为0.75%。公司表示已对相关业 务及明细进行全面核查，不存在其他应扣未扣情况。 按业务板块划分，医药流通业务2025年实现收入19,072.38万元，占总营收的57.87%，同比增长4.43%， 成为公司收入增长的主要驱动力。该增长主要得 ...

特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我 们的推送。 摘要： 【目的】建立以 SH-AP-2型阴离子交换柱为分离柱， 离子色谱 - 抑 制 电 导 检 测 法 同时测定水样中三氯乙酸、高氯酸盐的新方法。【方法】试验研究同时测定三氯乙酸、高氯酸 盐 的 色 谱 条 件 和 可 行 性 ， 优 化 确 定 色 谱 条 件 。 【 结 果 】 以 SH-AP-2 型 阴 离 子 交 换 柱 为 分 离 柱，以5%甲醇-15.0mmol /LNa 2 CO3 溶 液 为 淋 洗 液 ， 流 量 为 0.80mL/min ， 采 用 等 度 洗 脱的方式可将高氯酸盐、三氯乙酸与硫酸盐等水中常见阴离子完全分离，通过抑制电导检测， 高氯酸盐、三氯乙酸的峰面积或峰高与其质量浓度均在0.05～5.0mg/L范围内呈良好的线性 关系，相关系数为0.9996～0.9999，方法应用于水样中高氯酸盐、三氯乙酸的同时测定，加 标 回 收 率 在 98.2% ～ 107.7% ， 5 次 平 行 测 定 的 相 对 标 准 偏 差 （ RSD ） 小 于 6% ， 方 法 ...

Core Insights - China National Pharmaceutical Group (国药股份) is a leading pharmaceutical commercial enterprise, currently holding a 20% stake in Yichang Humanwell, which is expected to contribute approximately 500 million yuan in investment income in 2024 [1] - The company dominates the pharmaceutical direct sales market in Beijing and has a current market capitalization of approximately 22 billion yuan, which is below the reasonable valuation of 26.5 billion yuan, indicating potential undervaluation [1] - For 2024, the company is projected to achieve revenue of 50.597 billion yuan and a net profit attributable to shareholders of 2 billion yuan, with stable operating cash flow [1] - The pharmaceutical industry is influenced by centralized procurement policies, but fluctuations for distribution companies are relatively minor [1] Institutional View - As of February 13, 2026, the comprehensive target price for the stock is 36.49 yuan, indicating a potential upside of 26.35% from the latest stock price, with a forecasted net profit growth of 1.04% year-on-year for 2025 [2] Stock Performance - Over the past week (February 7-13, 2026), the stock price of China National Pharmaceutical Group experienced slight fluctuations, closing at 28.99 yuan on February 13, reflecting a decline of 0.82% during this period, with a volatility of 1.71% [3] - The stock performance was slightly better than the pharmaceutical commercial sector, which saw a decline of approximately 0.55% during the same timeframe [3] - The highest trading volume reached 138 million yuan on February 9, with a turnover rate of 0.44% on February 13, indicating stable market trading [3] - Technically, the stock price has been hovering around the 20-day moving average of 29.12 yuan, with support at 28.67 yuan and resistance at 29.53 yuan [3]

2016-2025年医药制造业企业数统计图 数据来源：国家统计局，智研咨询整理 知前沿，问智研。智研咨询是中国一流产业咨询机构，十数年持续深耕产业研究领域，提供深度产业研 究报告、商业计划书、可行性研究报告及定制服务等一站式产业咨询服务。专业的角度、品质化的服 务、敏锐的市场洞察力，专注于提供完善的产业解决方案，为您的投资决策赋能。 上市公司：国药现代（600420），昆药集团（600422），片仔癀（600436），千金药业（600479），津 药药业（600488），国药股份（600511），联环药业（600513），合富中国（603122），康惠制药 （603139），莎普爱思（603168），奥翔药业（603229），大参林（603233） 相关报告：智研咨询发布的《2026-2032年中国医药制造外包（CMO/CDMO）行业市场发展态势及未来 趋势研判报告》 2025年1-12月，医药制造业企业数（以下数据涉及的企业，均为规模以上工业企业，从2011年起，规模 以上工业企业起点标准由原来的年主营业务收入500万元提高到年主营业务收入2000万元）为9875个， 和上年同期相比，增加了82个，同比增长 ...

Investment Rating - The report provides an "Outperform" rating for multiple companies in the healthcare sector, including BeiGene, JD Health, WuXi Biologics, and others, indicating a positive outlook for these stocks [1]. Core Insights - The macro and industry environment is improving due to the resolution of policy uncertainties, the release of significant clinical data, and a resurgence in global M&A activity, leading to a notable increase in investor sentiment towards innovative drugs for 2026 [4][11]. - In oncology, the PD-1/VEGF dual antibody approach is transitioning from "mechanism validation" to "clinical and industrial resonance," with multiple global Phase III trials underway, expected to catalyze approvals and data releases within the year [5][17]. - The metabolic sector is seeing growth in the cash-pay market for GLP-1 drugs, driven by limited insurance coverage and high out-of-pocket costs, prompting companies to enhance accessibility through direct sales and pricing adjustments [6][25]. - In the autoimmune space, there is a growing concentration risk among major products from multinational corporations (MNCs), with new antibody platforms expected to yield significant data in 2026, potentially leading to new business development opportunities [7]. - The central nervous system (CNS) investment focus remains on advancing Aβ monoclonal antibody treatments, with key data expected to open up early intervention market opportunities [9]. Summary by Sections Oncology - The PD-1/VEGF dual antibody's clinical and industrial certainty is strengthening, with major companies conducting multiple global Phase III trials across high-value indications [17]. - The Pan-RAS precision therapy is entering a realization phase, with key Phase III data expected in 2026 for pancreatic cancer and NSCLC [22]. Metabolic - The cash-pay market for GLP-1 drugs is expanding due to limited insurance coverage, with companies like Eli Lilly and Novo Nordisk adopting different direct-to-consumer strategies to enhance accessibility [25][26]. - Small nucleic acid therapies are expected to upgrade treatment paradigms, showing competitive data in weight loss and safety profiles when combined with GLP-1 [30]. Autoimmune - MNCs are increasingly reliant on a few blockbuster products, with structural opportunities arising from new antibody platforms expected to report data in 2026 [7]. - The trend towards oral formulations in autoimmune diseases is gaining traction, offering advantages in adherence and competitive differentiation [7]. CNS - The focus in CNS remains on Aβ monoclonal antibody treatments, with advancements expected to shift treatment towards earlier intervention populations [9]. - New delivery methods, such as systemic administration of small nucleic acids, are being explored as complementary approaches [9].

（来源：劳动午报） 现场，院校、东城区与北京国有资本运营管理有限公司签约发布目标规模40亿元的"协和创新港"成果转 化基金，通用健康、华润医药、国药集团、中发展集团、联影集团、海尔集团、数坤科技、中欧医药健 康产业同学会、东城国资公司等9家"协和创新港"合作伙伴意向签约，并向"协和创新港"首席科学家颁 发聘书，向药物所、阜外医院等20余家首批入港项目及平台单位授牌。 据了解，"协和创新港"聚焦创新药物、新型疫苗、高端医疗器械、人工智能医疗等重点领域，构建"源 头创新-临床验证-成果转化-产业落地"的全链条闭环生态体系，形成"研发在院校、转化在东城、辐射京 津冀、带动全中国"的特色发展格局。该项目将分三阶段推进，起步区已完成改造并投入使用，计划到 2030年累计转化一批重大创新项目，培育数十家"协和系"高新技术企业，形成生物医药产业集群。东城 区将为项目提供空间载体、政策资源等全方位支持，双方将通过共建转化平台、共育专业人才，合力打 造医药健康创新策源地。 本报讯（记者 边磊） 近日，由中国医学科学院北京协和医学院（以下简称"院校"）与东城区委、东城 区人民政府主办的"协和创新港"项目启动会举行。会上，院校与东 ...

Group 1 - The "Xiehe Innovation Port" project was officially launched on February 2, with a cooperation agreement signed between the Chinese Academy of Medical Sciences Peking Union Medical College and the Dongcheng District government [2][3] - The project aims to focus on key areas such as innovative drugs, new vaccines, high-end medical devices, and artificial intelligence in healthcare, creating a benchmark innovation platform that integrates achievement transformation, industry incubation, resource docking, talent cultivation, and professional services [6] - The cooperation agreement includes five core components: provision of physical space and supporting services by Dongcheng District, special support policies, establishment of an integrated platform for technology breakthroughs and achievement transformation, creation of a talent cultivation base, and a governance model ensuring efficient operation [6][7]

Core Viewpoint - The A-share pharmaceutical retail sector is experiencing a significant rebound, driven by a new policy aimed at promoting high-quality development in the industry, which is expected to help around 700,000 pharmacies currently facing challenges [2][3]. Group 1: Industry Trends - The pharmaceutical retail industry is undergoing a wave of closures, with a projected net closure of 39,000 stores in 2024, significantly higher than the 3.8% closure rate in 2023 [5][6]. - The market is witnessing a shift from passive closures to proactive consolidation, as the new policy addresses industry pain points and encourages mergers and acquisitions [2][3][9]. - The concentration of the market is increasing, with the top 10 companies expected to reach a market share of over 35% by 2026, moving towards the levels seen in mature markets [9]. Group 2: Financial Performance - Major players in the industry are facing declining revenues and profits, with companies like YaoYao and GuoDa Pharmacy reporting significant drops in net profits, highlighting the financial strain on the sector [4][5]. - Only one out of six major private listed chains, Yifeng Pharmacy, is expected to achieve positive net profit growth in 2024, indicating a narrowing profitability landscape [5][6]. Group 3: Policy Impact - The new policy aims to standardize and optimize the merger and acquisition process, reducing costs and time for major chains, thus facilitating industry consolidation [7][9]. - The policy encourages a shift from a focus on drug sales to a broader health service model, aligning with changing consumer demands and promoting diversification in product offerings [8][9]. Group 4: Future Outlook - The industry is expected to evolve from merely selling drugs to becoming comprehensive health service providers, enhancing efficiency and better meeting consumer needs [10][11]. - The ongoing transformation is anticipated to eliminate inefficient capacities and elevate industry standards, marking a transition to a new phase of value growth [11].